Moderna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause.
Unveiling the Numbers:
Moderna's (...
MRNA seems to finding its feet part of wave-4. If market continues to hold current levels, and goes above..it can hit $120-129 part of wave-5.
Disclaimer: This is not financial advice. Please make your own decisions while making an investment.
Looks like the market is giving a break to this stock. I think is going to try the 95 resistance level. Looks oversold and bouncing up from a long term trendline. Also call options is an interesting choice but give it time like a month.
Analysts at the Oppenheimer brokerage company, as reported by Reuters , have upgraded the stock rating of Moderna Inc. to "outperforming the market," and the vaccine maker's CEO reiterated the company's goal of achieving sales growth by 2025.
The issuer's shares fell nearly 45% in 2023, marking its worst annual performance due to weak COVID-19 vaccine sales....
In the dynamic world of stock trading, there are some patterns which emerge that tell a story of market sentiment, investor behavior, and potential future movements. One such narrative is unfolding with Moderna Inc. (MRNA), where an intriguing pattern has caught my eye as we've seen a price rebound since November 2nd, 2023, the inverted scallop. The inverted...
Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role...
Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts. Founded in 2010, it focuses on the development of messenger RNA (mRNA) therapeutics, primarily vaccines.
Moderna is a leader in the field of mRNA technology, which uses messenger RNA to instruct cells to produce specific proteins. This technology has revolutionized...
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
Moderna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV).
The companies said that after about three years, the combination...
On MRNA we have a sell idea as you see on the chart because we have the breakout with force the vwap and the support by a big red candle follow by a large red volume.Thanks!
What's going on with Moderna? It's falling so hard
Company Discussion
I know that the Covid vaccine "growth" doesn't work either for Moderna or for Pfizer. Also, I read that their co-founder has sold more shares recently.
However, they are working on many more new drugs.
Were heading below until new variant of virus being spread by this company.
what is your...
Back to MRNA. Big misunderstanding or lack of homework by the market. US market is only 1/3 if sales. Clients are governments worldwide that order guaranteed doses as insurances. Some contracts APA are for 10 years ( even SAAS are not priced on 10 years visibility ). Last but not least. The price for a 1 dosis ( now packaged in a 1 shot syringe) is not anymore...
We are in a major daily demand zone here, I will be looking for prices to bounce off of these levels with substantial volume and will hold some long calls. Thank you for partaking of my analysis.
